Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GlaxoSmithKline : CureVac, GSK Report Positive Preclinical Data on Second Generation COVID-19 Jab

05/13/2021 | 08:49am EDT


ę MT Newswires 2021
All news about GLAXOSMITHKLINE PLC
06/24VIFOR PHARMAá : Appoints Former GlaxoSmithKline Executive as CEO; Shares Down 5%
MT
06/24Roche's Actemra gets U.S. FDA approval for hospitalized COVID-19 patients
RE
06/24Today on Wall Street: Hope for the best, prepare for the worse
06/24GLAXOSMITHKLINEá : Kepler Cheuvreux reiterates its Neutral rating
MD
06/24GLAXOSMITHKLINEá : Price Target From Credit Suisse Raised to GBP14 From GBP13 Bu..
MT
06/24GLAXOSMITHKLINEá : Credit Suisse Boosts GlaxoSmithKline PT, Maintains Underperfo..
MT
06/24GLAXOSMITHKLINEá : Deutsche Bank Lifts GlaxoSmithKline To Sell From Hold, Boosts..
MT
06/24GLAXOSMITHKLINEá : UBS remains Neutral
MD
06/24GLAXOSMITHKLINEá : Credit Suisse remains a Sell rating
MD
06/24ANALYST RECOMMENDATIONS : Beazley, BP, BWX Technologies, Cineworld, Nutanix...
More news
Financials
Sales 2021 33 138 M 46 171 M 46 171 M
Net income 2021 3 770 M 5 253 M 5 253 M
Net Debt 2021 21 587 M 30 077 M 30 077 M
P/E ratio 2021 19,1x
Yield 2021 5,67%
Capitalization 70 605 M 98 153 M 98 375 M
EV / Sales 2021 2,78x
EV / Sales 2022 2,61x
Nbr of Employees 94 066
Free-Float 92,3%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 1 411,00 GBX
Average target price 1 518,30 GBX
Spread / Average Target 7,60%
EPS Revisions
Managers and Directors
NameTitle
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC5.14%98 474
JOHNSON & JOHNSON3.34%428 269
ROCHE HOLDING AG10.19%321 632
PFIZER, INC.6.09%218 590
NOVARTIS AG1.55%207 926
ABBVIE INC.6.39%201 349